BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA A Cancer J Clin 2020;70:299-312. [DOI: 10.3322/caac.21613] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 45.0] [Reference Citation Analysis]
Number Citing Articles
1 Niu X, Sun J, Meng L, Fang T, Zhang T, Jiang J, Li H. A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction. Front Oncol 2020;10:590352. [PMID: 33392085 DOI: 10.3389/fonc.2020.590352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Graziano F, Iacopino DG, Cammarata G, Scalia G, Campanella C, Giannone AG, Porcasi R, Florena AM, Conway de Macario E, Macario AJ, Nicoletti GF, Caruso Bavisotto C. The Triad Hsp60-miRNAs-Extracellular Vesicles in Brain Tumors: Assessing Its Components for Understanding Tumorigenesis and Monitoring Patients. Applied Sciences 2021;11:2867. [DOI: 10.3390/app11062867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Boccellato C, Kolbe E, Peters N, Juric V, Fullstone G, Verreault M, Idbaih A, Lamfers MLM, Murphy BM, Rehm M. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. Cell Death Dis 2021;12:647. [PMID: 34168123 DOI: 10.1038/s41419-021-03927-x] [Reference Citation Analysis]
4 Wang X, Yang Q, Liu N, Bian Q, Gao M, Hou X. Clinical Value of TXNDC12 Combined With IDH and 1p19q as Biomarkers for Prognosis of Glioma. Pathol Oncol Res 2021;27:1609825. [PMID: 34629960 DOI: 10.3389/pore.2021.1609825] [Reference Citation Analysis]
5 Kong Z, Li Z, Chen J, Liu S, Liu D, Li J, Li N, Ma W, Feng F, Wang Y, Yang Z, Liu Z. Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.01.002] [Reference Citation Analysis]
6 Gómez-Oliva R, Domínguez-García S, Carrascal L, Abalos-Martínez J, Pardillo-Díaz R, Verástegui C, Castro C, Nunez-Abades P, Geribaldi-Doldán N. Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments. Front Oncol 2020;10:614295. [PMID: 33585240 DOI: 10.3389/fonc.2020.614295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Yu J, Sheng Z, Wu S, Gao Y, Yan Z, Bu C, Gu J, Bu Y, Deng K, Xu S, Chen Z, Zhang Q, Zemmar A, Hernesniemi J, Wang M, Liu G, Li T, Bu X. Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence. Front Oncol 2021;11:742037. [PMID: 34712610 DOI: 10.3389/fonc.2021.742037] [Reference Citation Analysis]
8 Zhu J, Su J. Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy. Indian J Microbiol 2022;62:23-31. [DOI: 10.1007/s12088-021-00962-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li C, Guo H, Wang C, Zhan W, Tan Q, Xie C, Sharma A, Sharma HS, Chen L, Zhang Z. Network pharmacological mechanism of Cinobufotalin against glioma. Prog Brain Res 2021;265:119-37. [PMID: 34560920 DOI: 10.1016/bs.pbr.2021.06.001] [Reference Citation Analysis]
10 Wang H, Shi L, Wang Z. A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma. Front Oncol 2021;11:756817. [PMID: 34804949 DOI: 10.3389/fonc.2021.756817] [Reference Citation Analysis]
11 Miles X, Vandevoorde C, Hunter A, Bolcaen J. MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. Front Oncol 2021;11:703442. [PMID: 34307171 DOI: 10.3389/fonc.2021.703442] [Reference Citation Analysis]
12 Ibarra LE. Cellular Trojan horses for delivery of nanomedicines to brain tumors: where do we stand and what is next? Nanomedicine (Lond) 2021;16:517-22. [PMID: 33634710 DOI: 10.2217/nnm-2021-0034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yu M, Yu S, Zhou W, Yi B, Liu Y. HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma. Int Immunopharmacol 2021;101:108293. [PMID: 34763232 DOI: 10.1016/j.intimp.2021.108293] [Reference Citation Analysis]
14 Yang X, Chen C, Li L, Xiao T, Zou YD, Zheng D. Current research advances in microRNA-mediated regulation of Krüppel-like factor 4 in cancer: a narrative review. Ann Transl Med 2021;9:948. [PMID: 34350263 DOI: 10.21037/atm-21-2347] [Reference Citation Analysis]
15 Attia N, Mashal M, Pemminati S, Omole A, Edmondson C, Jones W, Priyadarshini P, Mughal T, Aziz P, Zenick B, Perez A, Lacken M. Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies. Cells 2021;11:116. [PMID: 35011678 DOI: 10.3390/cells11010116] [Reference Citation Analysis]
16 Sun G, Zhuang W, Lin QT, Wang LM, Zhen YH, Xi SY, Lin XL. Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature. World J Clin Cases 2021; 9(12): 2845-2853 [PMID: 33969068 DOI: 10.12998/wjcc.v9.i12.2845] [Reference Citation Analysis]
17 Groblewska M, Mroczko B. Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities. Int J Mol Sci 2021;22:6126. [PMID: 34200145 DOI: 10.3390/ijms22116126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Liu J, Gao L, Zhu X, Geng R, Tao X, Xu H, Chen Z. Gasdermin D Is a Novel Prognostic Biomarker and Relates to TMZ Response in Glioblastoma. Cancers (Basel) 2021;13:5620. [PMID: 34830775 DOI: 10.3390/cancers13225620] [Reference Citation Analysis]
19 Chen B, Wang M, Huang R, Liao K, Wang T, Yang R, Zhang W, Shi Z, Ren L, Lv Q, Ma C, Lin Y, Qiu Y. Circular RNA circLGMN facilitates glioblastoma progression by targeting miR-127-3p/LGMN axis. Cancer Lett 2021;522:225-37. [PMID: 34582975 DOI: 10.1016/j.canlet.2021.09.030] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ayala-Domínguez L, Pérez-Cárdenas E, Avilés-Salas A, Medina LA, Lizano M, Brandan ME. Quantitative Imaging Parameters of Contrast-Enhanced Micro-Computed Tomography Correlate with Angiogenesis and Necrosis in a Subcutaneous C6 Glioma Model. Cancers (Basel) 2020;12:E3417. [PMID: 33217988 DOI: 10.3390/cancers12113417] [Reference Citation Analysis]
21 Li J, Hu X, Luo T, Lu Y, Feng Y, Zhang H, Liu D, Fan X, Wang Y, Jiang L, Wang Y, Hao X, Shi T, Wang Z. N-2-(phenylamino) benzamide derivatives as novel anti-glioblastoma agents: Synthesis and biological evaluation. Eur J Med Chem 2021;226:113817. [PMID: 34537445 DOI: 10.1016/j.ejmech.2021.113817] [Reference Citation Analysis]
22 Hsieh TH, Liang ML, Zheng JH, Lin YC, Yang YC, Vo TH, Liou JP, Yen Y, Chen CH. Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment. Cancers (Basel) 2021;13:6117. [PMID: 34885226 DOI: 10.3390/cancers13236117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tirrò E, Massimino M, Romano C, Martorana F, Pennisi MS, Stella S, Pavone G, Di Gregorio S, Puma A, Tomarchio C, Vitale SR, Manzella L, Vigneri P. Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. Front Oncol 2020;10:612385. [PMID: 33604294 DOI: 10.3389/fonc.2020.612385] [Reference Citation Analysis]
24 Xu K, Jiang X, Ariston Gabriel AN, Li X, Wang Y, Xu S. Evolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors. Front Cell Dev Biol 2021;9:737670. [PMID: 34692695 DOI: 10.3389/fcell.2021.737670] [Reference Citation Analysis]
25 Stanzani E, Pedrosa L, Bourmeau G, Anezo O, Noguera-Castells A, Esteve-Codina A, Passoni L, Matteoli M, de la Iglesia N, Seano G, Martínez-Soler F, Tortosa A. Dual Role of Integrin Alpha-6 in Glioblastoma: Supporting Stemness in Proneural Stem-Like Cells While Inducing Radioresistance in Mesenchymal Stem-Like Cells. Cancers (Basel) 2021;13:3055. [PMID: 34205341 DOI: 10.3390/cancers13123055] [Reference Citation Analysis]
26 Ye T, Li LL, Peng XM, Li Q. CYP1B1-AS1 Is a Novel Biomarker in Glioblastoma by Comprehensive Analysis. Dis Markers 2021;2021:8565943. [PMID: 35003394 DOI: 10.1155/2021/8565943] [Reference Citation Analysis]
27 An JM, Moon H, Verwilst P, Shin J, Kim BM, Park CK, Kim JS, Yeo SG, Kim HY, Kim D. Human Glioblastoma Visualization: Triple Receptor-Targeting Fluorescent Complex of Dye, SIWV Tetra-Peptide, and Serum Albumin Protein. ACS Sens 2021;6:2270-80. [PMID: 34100604 DOI: 10.1021/acssensors.1c00320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang G, Li H, Pan J, Yan T, Zhou H, Han X, Su L, Hou L, Xue X. Upregulated Expression of Cancer-Derived Immunoglobulin G Is Associated With Progression in Glioma. Front Oncol 2021;11:758856. [PMID: 34760705 DOI: 10.3389/fonc.2021.758856] [Reference Citation Analysis]
29 Han J, Yu X, Wang S, Wang Y, Liu Q, Xu H, Wang X. IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR. Front Cell Dev Biol 2022;9:659228. [DOI: 10.3389/fcell.2021.659228] [Reference Citation Analysis]
30 Ye J, Gao Y, Ji M, Yang Y, Wang Z, Wang B, Jin J, Li L, Wang H, Xu X, Liao H, Lian C, Xu Y, Li R, Sun T, Gao L, Li Y, Chen X, Liu Y. Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity. J Immunother Cancer 2021;9:e002753. [PMID: 34272308 DOI: 10.1136/jitc-2021-002753] [Reference Citation Analysis]
31 Karlsson J, Luly KM, Tzeng SY, Green JJ. Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies. Adv Drug Deliv Rev 2021;179:113999. [PMID: 34715258 DOI: 10.1016/j.addr.2021.113999] [Reference Citation Analysis]
32 Zhu Z, Zhang H, Chen B, Liu X, Zhang S, Zong Z, Gao M. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. Front Immunol 2020;11:588552. [PMID: 33329573 DOI: 10.3389/fimmu.2020.588552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
33 Xu J, Koval A, Katanaev VL. Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers. Front Oncol 2020;10:602817. [PMID: 33363033 DOI: 10.3389/fonc.2020.602817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Zhu H, Yu X, Zhang S, Shu K. Targeting the Complement Pathway in Malignant Glioma Microenvironments. Front Cell Dev Biol 2021;9:657472. [PMID: 33869223 DOI: 10.3389/fcell.2021.657472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chen Z, Zhuo S, He G, Tang J, Hao W, Gao WQ, Yang K, Xu H. Prognosis and Immunotherapy Significances of a Cancer-Associated Fibroblasts-Related Gene Signature in Gliomas. Front Cell Dev Biol 2021;9:721897. [PMID: 34778248 DOI: 10.3389/fcell.2021.721897] [Reference Citation Analysis]
36 Du K, Xia Q, Sun J, Feng F. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy. ACS Appl Mater Interfaces 2021;13:55851-61. [PMID: 34788006 DOI: 10.1021/acsami.1c16962] [Reference Citation Analysis]
37 Ma H, Li F, Shen G, Pan L, Liu W, Liang R, Lan T, Yang Y, Yang J, Liao J, Liu N. In vitro and in vivo evaluation of 211At-labeled fibroblast activation protein inhibitor for glioma treatment. Bioorg Med Chem 2022;55:116600. [PMID: 34999526 DOI: 10.1016/j.bmc.2021.116600] [Reference Citation Analysis]
38 Zhou L, Jiang Z, Shi Z, Zhao W, Lu Z, Xie Y, Zhang B, Lu H, Tan G, Wang Z. New Autophagy-Ferroptosis Gene Signature Predicts Survival in Glioma. Front Cell Dev Biol 2021;9:739097. [PMID: 34869322 DOI: 10.3389/fcell.2021.739097] [Reference Citation Analysis]
39 Kang RH, Park J, Kim J, Chowdhury T, Oh JH, Kim J, Shin J, Kim M, Park CK, Lee S, Lee JY, Kim D. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomater Sci Eng 2021. [PMID: 34196517 DOI: 10.1021/acsbiomaterials.1c00653] [Reference Citation Analysis]
40 Deng L, Zhai X, Liang P, Cui H. Overcoming TRAIL Resistance for Glioblastoma Treatment. Biomolecules 2021;11:572. [PMID: 33919846 DOI: 10.3390/biom11040572] [Reference Citation Analysis]
41 Jamjoom AM, Gahtani AY, Jamjoom AB. Predictors of Citation Rates in High-Impact Glioblastoma Clinical Trials. Cureus 2021;13:e19229. [PMID: 34877207 DOI: 10.7759/cureus.19229] [Reference Citation Analysis]
42 Rabab'h O, Al-Ramadan A, Shah J, Lopez-Negrete H, Gharaibeh A. Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival. Cureus 2021;13:e16061. [PMID: 34345547 DOI: 10.7759/cureus.16061] [Reference Citation Analysis]
43 Rinoldi C, Zargarian SS, Nakielski P, Li X, Liguori A, Petronella F, Presutti D, Wang Q, Costantini M, De Sio L, Gualandi C, Ding B, Pierini F. Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. Small Methods 2021;:2100402. [PMID: 34514087 DOI: 10.1002/smtd.202100402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
44 Di Nunno V, Franceschi E, Tosoni A, Di Battista M, Gatto L, Lamperini C, Minichillo S, Mura A, Bartolini S, Brandes AA. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev Anticancer Ther 2020;20:785-95. [PMID: 32799576 DOI: 10.1080/14737140.2020.1807949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Gao X, Jiang W, Ke Z, Huang Q, Chen L, Zhang G, Li C, Yu X. TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway. Biochem Biophys Res Commun 2022;586:34-41. [PMID: 34826698 DOI: 10.1016/j.bbrc.2021.11.061] [Reference Citation Analysis]
46 Eisenhut F, Engelhorn T, Arinrad S, Brandner S, Coras R, Putz F, Fietkau R, Doerfler A, Schmidt MA. A Comparison of Single- and Multiparametric MRI Models for Differentiation of Recurrent Glioblastoma from Treatment-Related Change. Diagnostics (Basel) 2021;11:2281. [PMID: 34943518 DOI: 10.3390/diagnostics11122281] [Reference Citation Analysis]
47 Luo X, Tu T, Zhong Y, Xu S, Chen X, Chen L, Yang F. AGAP2-AS1 May Promote the Occurrence and Development of Glioblastoma by Sponging miR-9-5p: Evidence From a ceRNA Network. Front Oncol 2021;11:607989. [PMID: 33889541 DOI: 10.3389/fonc.2021.607989] [Reference Citation Analysis]
48 Zhang N, Zheng B, Yao X, Huang X, Du J, Shen Y, Huang Z, Chen J, Lin Q, Lan W, Lin W, Ma W. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment. Biochem Biophys Res Commun 2021;551:38-45. [PMID: 33714758 DOI: 10.1016/j.bbrc.2021.02.112] [Reference Citation Analysis]
49 Parrozzani R, Lombardi G, Midena E, Londei D, Padovan M, Marchione G, Caccese M, Midena G, Zagonel V, Frizziero L. Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study. Front Oncol 2020;10:593461. [PMID: 33154952 DOI: 10.3389/fonc.2020.593461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Vallée A, Lecarpentier Y, Vallée JN. Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification. Biomedicines 2021;9:619. [PMID: 34070746 DOI: 10.3390/biomedicines9060619] [Reference Citation Analysis]
51 Cao Y, Zhou H, Chen X, Li Y, Hu J, Zhou G, Wang L. Recent insight into the role of RING-finger E3 ligases in glioma. Biochem Soc Trans 2021;49:519-29. [PMID: 33544148 DOI: 10.1042/BST20201060] [Reference Citation Analysis]
52 Sung CH, Tsuang FY, Lin CP, Chan KC, Chou WH, Wu CY. Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation. Sci Rep 2021;11:16489. [PMID: 34389754 DOI: 10.1038/s41598-021-95851-5] [Reference Citation Analysis]
53 Tsidulko AY, Shevelev OB, Khotskina AS, Kolpakova MA, Suhovskih AV, Kazanskaya GM, Volkov AM, Aidagulova SV, Zavyalov EL, Grigorieva EV. Chemotherapy-Induced Degradation of Glycosylated Components of the Brain Extracellular Matrix Promotes Glioblastoma Relapse Development in an Animal Model. Front Oncol 2021;11:713139. [PMID: 34350124 DOI: 10.3389/fonc.2021.713139] [Reference Citation Analysis]
54 Putavet DA, de Keizer PLJ. Residual Disease in Glioma Recurrence: A Dangerous Liaison with Senescence. Cancers (Basel) 2021;13:1560. [PMID: 33805316 DOI: 10.3390/cancers13071560] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Huang Y, Wang Y, Huang Z. A Specific Peptide Vaccine Against IDH1(R132H) Glioma. Neurosci Bull 2021. [PMID: 34739683 DOI: 10.1007/s12264-021-00791-9] [Reference Citation Analysis]
56 Li J, Sun Y, Sun X, Zhao X, Ma Y, Wang Y, Zhang X. AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide. Sci Rep 2021;11:17348. [PMID: 34462446 DOI: 10.1038/s41598-021-96647-3] [Reference Citation Analysis]
57 Dragoj M, Stojkovska J, Stanković T, Dinić J, Podolski-Renić A, Obradović B, Pešić M. Development and Validation of a Long-Term 3D Glioblastoma Cell Culture in Alginate Microfibers as a Novel Bio-Mimicking Model System for Preclinical Drug Testing. Brain Sci 2021;11:1025. [PMID: 34439644 DOI: 10.3390/brainsci11081025] [Reference Citation Analysis]
58 Ustun M, Rahmani Dabbagh S, Ilci IS, Bagci-Onder T, Tasoglu S. Glioma-on-a-Chip Models. Micromachines (Basel) 2021;12:490. [PMID: 33926127 DOI: 10.3390/mi12050490] [Reference Citation Analysis]
59 Li J, Wang W, Wang J, Cao Y, Wang S, Zhao J. Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma. Front Oncol 2021;11:678226. [PMID: 34055646 DOI: 10.3389/fonc.2021.678226] [Reference Citation Analysis]
60 Han H, Oberacker E, Kuehne A, Wang S, Eigentler TW, Grass E, Niendorf T. Multi-Channel RF Supervision Module for Thermal Magnetic Resonance Based Cancer Therapy. Cancers (Basel) 2021;13:1001. [PMID: 33670862 DOI: 10.3390/cancers13051001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 Zhang W, Cai YY, Wang XL, Wang XX, Li Y, Han GY, Chu YJ, Zhang YX, Hao FR. Bone Metastases of Glioblastoma: A Case Report and Review of the Literature. Front Oncol 2021;11:705455. [PMID: 34646764 DOI: 10.3389/fonc.2021.705455] [Reference Citation Analysis]
62 Rodríguez Aguilar L, Vilchez ML, Milla Sanabria LN. Targeting glioblastoma stem cells: The first step of photodynamic therapy. Photodiagnosis Photodyn Ther 2021;36:102585. [PMID: 34687963 DOI: 10.1016/j.pdpdt.2021.102585] [Reference Citation Analysis]
63 Jiang H, Yu K, Cui Y, Ren X, Li M, Yang C, Zhao X, Zhu Q, Lin S. Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study. Front Immunol 2021;12:632547. [PMID: 34025640 DOI: 10.3389/fimmu.2021.632547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Yang Z, Shi H, Chinnathambi A, Salmen SH, Alharbi SA, Veeraraghavan VP, Surapaneni KM, Arulselvan P. Arbutin exerts anticancer activity against rat C6 glioma cells by inducing apoptosis and inhibiting the inflammatory markers and P13/Akt/mTOR cascade. J Biochem Mol Toxicol 2021;:e22857. [PMID: 34338399 DOI: 10.1002/jbt.22857] [Reference Citation Analysis]
65 Luan XZ, Wang HR, Xiang W, Li SJ, He H, Chen LG, Wang JM, Zhou J. Extracranial multiorgan metastasis from primary glioblastoma: A case report. World J Clin Cases 2021; 9(33): 10300-10307 [PMID: 34904103 DOI: 10.12998/wjcc.v9.i33.10300] [Reference Citation Analysis]
66 Chen B, Chen C, Zhang Y, Xu J. Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017. BMC Cancer 2021;21:54. [PMID: 33430813 DOI: 10.1186/s12885-020-07778-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Ylanan AMD, Pascual JSG, Cruz-Lim EMD, Ignacio KHD, Cañal JPA, Khu KJO. Intraoperative radiotherapy for glioblastoma: A systematic review of techniques and outcomes. J Clin Neurosci 2021;93:36-41. [PMID: 34656258 DOI: 10.1016/j.jocn.2021.08.022] [Reference Citation Analysis]
68 Dumitru CA, Brouwer E, Stelzer T, Nocerino S, Rading S, Wilkens L, Sandalcioglu IE, Karsak M. Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma. Cancers (Basel) 2021;13:2624. [PMID: 34071761 DOI: 10.3390/cancers13112624] [Reference Citation Analysis]
69 Liu Z, Zhang W, Cheng X, Wang H, Bian L, Wang J, Han Z, Wang Y, Lian X, Liu B, Ren Z, Zhang B, Jiang Z, Lin Z, Gao Y. Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients. Mol Med 2021;27:52. [PMID: 34051735 DOI: 10.1186/s10020-021-00316-0] [Reference Citation Analysis]
70 Mahinfar P, Mokhtarzadeh A, Baradaran B, Siasi Torbati E. Antiproliferative activity of CD44 siRNA-PEI-PEG nanoparticles in glioblastoma: involvement of AKT signaling. Res Pharm Sci 2022;17:78-85. [PMID: 34909046 DOI: 10.4103/1735-5362.329928] [Reference Citation Analysis]
71 Ji H, Ba Y, Ma S, Hou K, Mi S, Gao X, Jin J, Gong Q, Liu T, Wang F, Liu Z, Li S, Du J, Hu S. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy. Front Immunol 2021;12:729359. [PMID: 34566988 DOI: 10.3389/fimmu.2021.729359] [Reference Citation Analysis]
72 Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D, Mao Y, Ma W, Mao Q, You Y, Jiang C, Yang X, Kang C, Qiu X, Li W, Li S, Chen L, Li X, Liu Z, Wang W, Bai H, Yao Y, Li S, Wu A, Sai K, Li G, Yao K, Wei X, Liu X, Zhang Z, Dai Y, Lv S, Wang L, Lin Z, Dong J, Xu G, Ma X, Zhang W, Zhang C, Chen B, You G, Wang Y, Wang Y, Bao Z, Yang P, Fan X, Liu X, Zhao Z, Wang Z, Li Y, Wang Z, Li G, Fang S, Li L, Liu Y, Liu S, Shan X, Liu Y, Chai R, Hu H, Chen J, Yan W, Cai J, Wang H, Chen L, Yang Y, Wang Y, Han L, Wang Q; Chinese Glioma Cooperative Group (CGCG)., Society for Neuro‐Oncology of China (SNO-China)., Chinese Brain Cancer Association (CBCA)., Chinese Glioma Genome Atlas (CGGA)., Asian Glioma Genome Atlas (AGGA) network. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 2021;499:60-72. [PMID: 33166616 DOI: 10.1016/j.canlet.2020.10.050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
73 Śledzińska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA. Prognostic and Predictive Biomarkers in Gliomas. Int J Mol Sci 2021;22:10373. [PMID: 34638714 DOI: 10.3390/ijms221910373] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Bi H, Zhang C. Extrinsic factors associated with the response to immunotherapy in glioblastoma. Cancer Lett 2021;511:47-55. [PMID: 33933551 DOI: 10.1016/j.canlet.2021.04.018] [Reference Citation Analysis]
75 Yuan F, Cong Z, Cai X, Zhu J, Yuan L, Wang Y, Tang C, Ma C. BACH1 as a potential target for immunotherapy in glioblastomas. Int Immunopharmacol 2021;103:108451. [PMID: 34923423 DOI: 10.1016/j.intimp.2021.108451] [Reference Citation Analysis]
76 Bagherian A, Roudi B, Masoudian N, Mirzaei H. Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib. Food Funct 2021;12:10926-37. [PMID: 34647945 DOI: 10.1039/d1fo01611c] [Reference Citation Analysis]
77 Zhao C, Li LQ, Yang FD, Wei RL, Wang MK, Song DX, Guo XY, Du W, Wei XT. A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma. Front Oncol 2020;10:591352. [PMID: 33363021 DOI: 10.3389/fonc.2020.591352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Klein E, Hau AC, Oudin A, Golebiewska A, Niclou SP. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy. Front Oncol 2020;10:604121. [PMID: 33364198 DOI: 10.3389/fonc.2020.604121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
79 Prabhudesai S, Wang NC, Ahluwalia V, Huan X, Bapuraj JR, Banovic N, Rao A. Stratification by Tumor Grade Groups in a Holistic Evaluation of Machine Learning for Brain Tumor Segmentation. Front Neurosci 2021;15:740353. [PMID: 34690680 DOI: 10.3389/fnins.2021.740353] [Reference Citation Analysis]
80 Alvarez-Arellano L, Salazar-García M, Corona JC. Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases. Molecules 2020;25:E5597. [PMID: 33260783 DOI: 10.3390/molecules25235597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
81 Wei QT, Liu BY, Ji HY, Lan YF, Tang WH, Zhou J, Zhong XY, Lian CL, Huang QZ, Wang CY, Xu YM, Guo HB. Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas. Mol Ther Oncolytics 2021;22:114-28. [PMID: 34514093 DOI: 10.1016/j.omto.2021.08.004] [Reference Citation Analysis]
82 Tu S, Lin X, Qiu J, Zhou J, Wang H, Hu S, Yao Y, Wang Y, Deng Y, Zhou Y, Shao A. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma. Front Immunol 2021;12:650105. [PMID: 34394072 DOI: 10.3389/fimmu.2021.650105] [Reference Citation Analysis]
83 Li K, Yao T, Zhang Y, Li W, Wang Z. NEAT1 as a competing endogenous RNA in tumorigenesis of various cancers: Role, mechanism and therapeutic potential. Int J Biol Sci 2021;17:3428-40. [PMID: 34512157 DOI: 10.7150/ijbs.62728] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Ailioaie LM, Ailioaie C, Litscher G. Latest Innovations and Nanotechnologies with Curcumin as a Nature-Inspired Photosensitizer Applied in the Photodynamic Therapy of Cancer. Pharmaceutics 2021;13:1562. [PMID: 34683855 DOI: 10.3390/pharmaceutics13101562] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Xue C, Li G, Lu J, Li L. Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. Signal Transduct Target Ther 2021;6:400. [PMID: 34815385 DOI: 10.1038/s41392-021-00788-w] [Reference Citation Analysis]
86 Persico P, Lorenzi E, Dipasquale A, Pessina F, Navarria P, Politi LS, Santoro A, Simonelli M. Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. J Clin Med 2021;10:1367. [PMID: 33810532 DOI: 10.3390/jcm10071367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Lu Y, Feng Y, Li Z, Li J, Zhang H, Hu X, Jiang W, Shi T, Wang Z. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression. Eur J Med Chem 2022;227:113908. [PMID: 34656900 DOI: 10.1016/j.ejmech.2021.113908] [Reference Citation Analysis]
88 Bazan NG, Reid MM, Flores VAC, Gallo JE, Lewis W, Belayev L. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration. Cancer Metastasis Rev 2021;40:643-7. [PMID: 34519960 DOI: 10.1007/s10555-021-09987-x] [Reference Citation Analysis]
89 Sluter MN, Hou R, Li L, Yasmen N, Yu Y, Liu J, Jiang J. EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics. J Med Chem 2021;64:11816-36. [PMID: 34352171 DOI: 10.1021/acs.jmedchem.1c00816] [Reference Citation Analysis]
90 Klimenko A, Rodina EE, Silachev D, Begun M, Babenko VA, Benditkis AS, Kozlov AS, Krasnovsky AA, Khotimchenko YS, Katanaev VL. Chlorin Endogenous to the North Pacific Brittle Star Ophiura sarsii for Photodynamic Therapy Applications in Breast Cancer and Glioblastoma Models. Biomedicines 2022;10:134. [DOI: 10.3390/biomedicines10010134] [Reference Citation Analysis]
91 Lin W, Sun Y, Qiu X, Huang Q, Kong L, Lu JJ. VMP1, a novel prognostic biomarker, contributes to glioma development by regulating autophagy. J Neuroinflammation 2021;18:165. [PMID: 34311746 DOI: 10.1186/s12974-021-02213-z] [Reference Citation Analysis]
92 Guven DC, Aksun MS, Cakir IY, Kilickap S, Kertmen N. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme. Future Oncol 2021;17:4405-13. [PMID: 34409854 DOI: 10.2217/fon-2021-0681] [Reference Citation Analysis]
93 Bryukhovetskiy I, Kosianova A, Zaitsev S, Pak O, Sharma A, Sharma HS. Glioblastoma: What can we do for these patients today and what will we be able to do in the future? Prog Brain Res 2021;265:99-118. [PMID: 34560928 DOI: 10.1016/bs.pbr.2021.04.012] [Reference Citation Analysis]
94 Hernández A, Domènech M, Muñoz-mármol AM, Carrato C, Balana C. Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment. Cells 2021;10:3529. [DOI: 10.3390/cells10123529] [Reference Citation Analysis]
95 Sfifou F, Ouzir M, Hakkou EM, Obtel M, Errihani H, Bouzidi AA, Abouqal R, El Ouahabi A, Cherradi N. Immunohistochemical expression of HIF-1α, IDH1 and TP53: Prognostic profile of Moroccan patients with diffuse glioma. J Chem Neuroanat 2022;119:102056. [PMID: 34871733 DOI: 10.1016/j.jchemneu.2021.102056] [Reference Citation Analysis]
96 Li X, Sun L, Wang X, Wang N, Xu K, Jiang X, Xu S. A Five Immune-Related lncRNA Signature as a Prognostic Target for Glioblastoma. Front Mol Biosci 2021;8:632837. [PMID: 33665208 DOI: 10.3389/fmolb.2021.632837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
97 Ljubimov VA, Ramesh A, Davani S, Danielpour M, Breunig JJ, Black KL. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Adv Drug Deliv Rev 2021;:114033. [PMID: 34808227 DOI: 10.1016/j.addr.2021.114033] [Reference Citation Analysis]
98 Lara-Velazquez M, Shireman JM, Lehrer EJ, Bowman KM, Ruiz-Garcia H, Paukner MJ, Chappell RJ, Dey M. A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:662302. [PMID: 34046356 DOI: 10.3389/fonc.2021.662302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Rao D, Yu C, Sheng J, Lv E, Huang W. The Emerging Roles of circFOXO3 in Cancer. Front Cell Dev Biol 2021;9:659417. [PMID: 34150756 DOI: 10.3389/fcell.2021.659417] [Reference Citation Analysis]
100 Mokgautsi N, Wen YT, Lawal B, Khedkar H, Sumitra MR, Wu ATH, Huang HS. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties. Int J Mol Sci 2021;22:2464. [PMID: 33671112 DOI: 10.3390/ijms22052464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Li W, Soufiany I, Lyu X, Lu C, Wei Y, Shi Z, You Y. SP1-upregulated LBX2-AS1 promotes the progression of glioma by targeting the miR-491-5p/LIF axis. J Cancer 2021;12:6989-7002. [PMID: 34729101 DOI: 10.7150/jca.63289] [Reference Citation Analysis]
102 Zalles M, Smith N, Saunders D, Lerner M, Fung KM, Battiste J, Towner RA. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007. J Cell Mol Med 2021. [PMID: 34910361 DOI: 10.1111/jcmm.17133] [Reference Citation Analysis]
103 Mavroidi B, Kaminari A, Makrypidi K, Shegani A, Bouziotis P, Pirmettis I, Papadopoulos M, Sagnou M, Pelecanou M. Biological evaluation of complexes of cyclopentadienyl M(CO)3+ (M = Re, 99mTc) with high blood-brain barrier penetration potential as brain cancer agents. Invest New Drugs 2022. [PMID: 35024984 DOI: 10.1007/s10637-022-01211-z] [Reference Citation Analysis]
104 Chen M, Medarova Z, Moore A. Role of microRNAs in glioblastoma. Oncotarget 2021;12:1707-23. [PMID: 34434499 DOI: 10.18632/oncotarget.28039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Zhang M, Zhou Z, Liu Z, Liu F, Zhao C. Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis. PeerJ 2022;10:e12768. [DOI: 10.7717/peerj.12768] [Reference Citation Analysis]
106 Chang J, Wang L, Zhou X, Yuan J, Xu W. The CBL-LSD1-CXCL8 axis regulates methionine metabolism in glioma. Cytokine 2022;151:155789. [PMID: 34998158 DOI: 10.1016/j.cyto.2021.155789] [Reference Citation Analysis]
107 Fu M, Zhang J, Li W, He S, Zhang J, Tennant D, Hua W, Mao Y. Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma. J Transl Med 2021;19:404. [PMID: 34565408 DOI: 10.1186/s12967-021-03083-y] [Reference Citation Analysis]
108 Nwagwu CD, Adamson DC. Can we rely on synthetic pharmacotherapy for the treatment of glioblastoma? Expert Opin Pharmacother 2021;:1-12. [PMID: 34219576 DOI: 10.1080/14656566.2021.1950139] [Reference Citation Analysis]
109 Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C, Chen Y. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther 2021;6:74. [PMID: 33611339 DOI: 10.1038/s41392-020-00450-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 37] [Article Influence: 19.0] [Reference Citation Analysis]
110 Shi J, Chen G, Dong X, Li H, Li S, Cheng S, Li Y, Wang L, Yuan J, Qian Z, Dong J. METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner. Front Oncol 2021;11:702983. [PMID: 34336690 DOI: 10.3389/fonc.2021.702983] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Cataldi S, Arcuri C, Lazzarini A, Nakashidze I, Ragonese F, Fioretti B, Ferri I, Conte C, Codini M, Beccari T, Curcio F, Albi E. Effect of 1α,25(OH)2 Vitamin D3 in Mutant P53 Glioblastoma Cells: Involvement of Neutral Sphingomyelinase1. Cancers (Basel) 2020;12:E3163. [PMID: 33126474 DOI: 10.3390/cancers12113163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
112 Putthisen S, Silsirivanit A, Panawan O, Niibori-Nambu A, Nishiyama-Ikeda Y, Ma-In P, Luang S, Ohta K, Muisuk K, Wongkham S, Araki N. Targeting alpha2,3-sialylated glycan in glioma stem-like cells by Maackia amurensis lectin-II: A promising strategy for glioma treatment. Exp Cell Res 2022;410:112949. [PMID: 34843714 DOI: 10.1016/j.yexcr.2021.112949] [Reference Citation Analysis]
113 Cornelison R, Marrah L, Horter D, Lynch S, Li H. Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma. IJMS 2021;22:13635. [DOI: 10.3390/ijms222413635] [Reference Citation Analysis]
114 Ye X, Liu X, Gao M, Gong L, Tian F, Shen Y, Hu H, Sun G, Zou Y, Gong Y. CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription. Front Oncol 2021;11:638802. [PMID: 33869025 DOI: 10.3389/fonc.2021.638802] [Reference Citation Analysis]
115 Wang X, Gao M, Ye J, Jiang Q, Yang Q, Zhang C, Wang S, Zhang J, Wang L, Wu J, Zhan H, Hou X, Han D, Zhao S. An Immune Gene-Related Five-lncRNA Signature for to Predict Glioma Prognosis. Front Genet 2020;11:612037. [PMID: 33391355 DOI: 10.3389/fgene.2020.612037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
116 Hartnett S, Kroll D, Vogelbaum MA. Surgical Adjuncts for Glioblastoma. Neurosurg Clin N Am 2021;32:83-91. [PMID: 33223029 DOI: 10.1016/j.nec.2020.08.005] [Reference Citation Analysis]
117 Ye Z, Ai X, Zhao L, Fei F, Wang P, Zhou S. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics. Oncogene 2021;40:6059-70. [PMID: 34556813 DOI: 10.1038/s41388-021-02010-1] [Reference Citation Analysis]
118 Sheng Z, Yu J, Deng K, Andrade-Barazarte H, Zemmar A, Li S, Li N, Yan Z, Chen Z, Sun Y, Hernesniemi J, Bu X. Characterizing the Genomic Landscape of Brain Glioma With Circulating Tumor DNA From Tumor In Situ Fluid. Front Oncol 2021;11:584988. [PMID: 33868989 DOI: 10.3389/fonc.2021.584988] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 Calabrese G, De Luca G, Nocito G, Rizzo MG, Lombardo SP, Chisari G, Forte S, Sciuto EL, Conoci S. Carbon Dots: An Innovative Tool for Drug Delivery in Brain Tumors. Int J Mol Sci 2021;22:11783. [PMID: 34769212 DOI: 10.3390/ijms222111783] [Reference Citation Analysis]
120 Liu Y, Wang X, Li J, Tang J, Li B, Zhang Y, Gu N, Yang F. Sphingosine 1-Phosphate Liposomes for Targeted Nitric Oxide Delivery to Mediate Anticancer Effects against Brain Glioma Tumors. Adv Mater 2021;33:e2101701. [PMID: 34106489 DOI: 10.1002/adma.202101701] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Fiani B, Covarrubias C, Onyedimma C, Jarrah R. Neurocytological Advances in the Treatment of Glioblastoma Multiforme. Cureus 2021;13:e16301. [PMID: 34405064 DOI: 10.7759/cureus.16301] [Reference Citation Analysis]
122 Singh RR, Reindl KM. Glutathione S-Transferases in Cancer. Antioxidants (Basel) 2021;10:701. [PMID: 33946704 DOI: 10.3390/antiox10050701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
123 Han J, Jing Y, Han F, Sun P. Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma. BMC Neurol 2021;21:447. [PMID: 34781885 DOI: 10.1186/s12883-021-02477-1] [Reference Citation Analysis]
124 Li T, Yang Z, Li H, Zhu J, Wang Y, Tang Q, Shi Z. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. Lab Invest 2021. [PMID: 34697421 DOI: 10.1038/s41374-021-00682-7] [Reference Citation Analysis]
125 Ji H, Zhao H, Jin J, Liu Z, Gao X, Wang F, Dong J, Yan X, Zhang J, Wang N, Du J, Hu S. Novel Immune-Related Gene-Based Signature Characterizing an Inflamed Microenvironment Predicts Prognosis and Radiotherapy Efficacy in Glioblastoma. Front Genet 2022;12:736187. [DOI: 10.3389/fgene.2021.736187] [Reference Citation Analysis]
126 Zimmer J, Castriconi R, Scaglione S. Editorial: Recent 3D Tumor Models for Testing Immune-Mediated Therapies. Front Immunol 2021;12:798493. [PMID: 34868086 DOI: 10.3389/fimmu.2021.798493] [Reference Citation Analysis]
127 Guo X, Piao H. Research Progress of circRNAs in Glioblastoma. Front Cell Dev Biol 2021;9:791892. [PMID: 34881248 DOI: 10.3389/fcell.2021.791892] [Reference Citation Analysis]
128 Li G, Zhang Z, Cai L, Tang X, Huang J, Yu L, Wang G, Zhong K, Cao Y, Liu C, Wang Y, Tong A, Zhou L. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma. Oncoimmunology 2021;10:1983306. [PMID: 34595061 DOI: 10.1080/2162402X.2021.1983306] [Reference Citation Analysis]
129 Xu Y, Ye L, Geng R, Hu P, Sun Q, Tong S, Yuan F, Chen Q. Development and Verification of the Amino Metabolism-Related and Immune-Associated Prognosis Signature in Gliomas. Front Oncol 2021;11:774332. [PMID: 34804978 DOI: 10.3389/fonc.2021.774332] [Reference Citation Analysis]
130 Chen Q, Jin J, Huang X, Wu F, Huang H, Zhan R. EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion. J Exp Clin Cancer Res 2021;40:160. [PMID: 33964937 DOI: 10.1186/s13046-021-01954-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
131 Grigorieva EV. Radiation Effects on Brain Extracellular Matrix. Front Oncol 2020;10:576701. [PMID: 33134175 DOI: 10.3389/fonc.2020.576701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
132 Borja AJ, Hancin EC, Raynor WY, Ayubcha C, Detchou DK, Werner TJ, Revheim ME, Alavi A. A Critical Review of PET Tracers Used for Brain Tumor Imaging. PET Clin 2021;16:219-31. [PMID: 33589386 DOI: 10.1016/j.cpet.2020.12.004] [Reference Citation Analysis]
133 Ganai SA, Sheikh FA, Baba ZA, Mir MA, Mantoo MA, Yatoo MA. Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytotherapy Research 2021;35:3509-32. [DOI: 10.1002/ptr.7044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
134 Zhao C, Li L, Guo X, Song D, Wang M, Zhai Y, Yang F, Xue Y, Wei X. Preoperative Predictors of Early Mortality Risk in Isocitrate Dehydrogenase-Wild-Type Glioblastoma Patients Treated with Standard Therapy. Cancer Manag Res 2021;13:1159-68. [PMID: 33603461 DOI: 10.2147/CMAR.S290053] [Reference Citation Analysis]
135 Jandrey EHF, Bezerra M, Inoue LT, Furnari FB, Camargo AA, Costa ÉT. A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas. Front Oncol 2021;11:652133. [PMID: 34178638 DOI: 10.3389/fonc.2021.652133] [Reference Citation Analysis]
136 Bunevicius A, Pikis S, Kondziolka D, Patel DN, Bernstein K, Sulman EP, Lee CC, Yang HC, Delabar V, Mathieu D, Cifarelli CP, Arsanious DE, Dahshan BA, Weir JS, Speckter H, Mota A, Tripathi M, Kumar N, Warnick RE, Peker S, Samanci Y, Barnett G, Hefnawi FE, Al Sideiri G, Sheehan J. Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study. J Neurooncol 2021;155:343-51. [PMID: 34797526 DOI: 10.1007/s11060-021-03883-8] [Reference Citation Analysis]
137 Shi Y, Kong Z, Liu P, Hou G, Wu J, Ma W, Cheng X, Wang Y. Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors. Cells 2021;10:1142. [PMID: 34068501 DOI: 10.3390/cells10051142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Wei P, Jiang J, Xiao M, Zeng M, Liu X, Zhao B, Chen F. The transcript ENST00000444125 of lncRNA LINC01503 promotes cancer stem cell properties of glioblastoma cells via reducing FBXW1 mediated GLI2 degradation. Exp Cell Res 2022;412:113009. [PMID: 34990616 DOI: 10.1016/j.yexcr.2022.113009] [Reference Citation Analysis]
139 Wang Y, Shen H, Sun Q, Zhao L, Liu H, Ye L, Xu Y, Cai J, Li Y, Gao L, Tan Y, Liu B, Chen Q. The New PI3K/mTOR Inhibitor GNE-477 Inhibits the Malignant Behavior of Human Glioblastoma Cells. Front Pharmacol 2021;12:659511. [PMID: 34381355 DOI: 10.3389/fphar.2021.659511] [Reference Citation Analysis]
140 Su X, Yang Y, Yang Q, Pang B, Sun S, Wang Y, Qiao Q, Guo C, Liu H, Pang Q. NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma. BMC Cancer 2021;21:1181. [PMID: 34740322 DOI: 10.1186/s12885-021-08933-y] [Reference Citation Analysis]
141 Scott AJ, Lyssiotis CA, Wahl DR. Clinical Targeting of Altered Metabolism in High-Grade Glioma. Cancer J 2021;27:386-94. [PMID: 34570453 DOI: 10.1097/PPO.0000000000000550] [Reference Citation Analysis]
142 Singh K, Hotchkiss KM, Mohan AA, Reedy JL, Sampson JH, Khasraw M. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer 2021;9:e003679. [PMID: 34795007 DOI: 10.1136/jitc-2021-003679] [Reference Citation Analysis]
143 Tong N, He Z, Ma Y, Wang Z, Huang Z, Cao H, Xu L, Zou Y, Wang W, Yi C, Yin Z, Wang Q. Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy? Front Cell Dev Biol 2021;9:706286. [PMID: 34368156 DOI: 10.3389/fcell.2021.706286] [Reference Citation Analysis]
144 Wang X, Wang H, Xu J, Hou X, Zhan H, Zhen Y. Double-targeting CDCA8 and E2F1 inhibits the growth and migration of malignant glioma. Cell Death Dis 2021;12:146. [PMID: 33542211 DOI: 10.1038/s41419-021-03405-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Meng Q, Zhou J, You F, Wu Y, Yang L, Wang Y, Zhang X, Gao S, Yu R, Yin X. A novel biphenyl diester derivative, AB38b, inhibits glioblastoma cell growth via the ROS-AKT/mTOR pathway. Biochem Pharmacol 2021;:114795. [PMID: 34687671 DOI: 10.1016/j.bcp.2021.114795] [Reference Citation Analysis]
146 Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Bernal-Crespo V, Behymer MM, Knipp GT, Yun Y, Veronesi MC, Sinn AL, Pollok KE, Brutkiewicz RR, Nevel KS, Matosevic S. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proc Natl Acad Sci U S A 2021;118:e2107507118. [PMID: 34740973 DOI: 10.1073/pnas.2107507118] [Reference Citation Analysis]
147 Yang H, Wei L, Xun Y, Yang A, You H. BRD4: An emerging prospective therapeutic target in glioma. Mol Ther Oncolytics 2021;21:1-14. [PMID: 33851008 DOI: 10.1016/j.omto.2021.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
148 Politko MO, Tsidulko AY, Pashkovskaya OA, Kuper KE, Suhovskih AV, Kazanskaya GM, Klyushova LS, Sokolov DK, Volkov AM, Kliver EE, Zheravin AA, Aidagulova SV, Grigorieva EV. Multiple Irradiation Affects Cellular and Extracellular Components of the Mouse Brain Tissue and Adhesion and Proliferation of Glioblastoma Cells in Experimental System In Vivo. Int J Mol Sci 2021;22:13350. [PMID: 34948147 DOI: 10.3390/ijms222413350] [Reference Citation Analysis]
149 Mirzaei S, Mahabady MK, Zabolian A, Abbaspour A, Fallahzadeh P, Noori M, Hashemi F, Hushmandi K, Daneshi S, Kumar AP, Aref AR, Samarghandian S, Makvandi P, Khan H, Hamblin MR, Ashrafizadeh M, Zarrabi A. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems. Life Sci 2021;275:119368. [PMID: 33741417 DOI: 10.1016/j.lfs.2021.119368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
150 Zhao J, He D, Lai HM, Xu Y, Luo Y, Li T, Liang J, Yang X, Guo L, Ke Y, Zhou H, Wu W, Guo H, Sun H. Comprehensive histological imaging of native microbiota in human glioma. Journal of Biophotonics. [DOI: 10.1002/jbio.202100351] [Reference Citation Analysis]
151 Wang R, Liu T, Chen J, Zhang D. Paradol Induces Cell Cycle Arrest and Apoptosis in Glioblastoma Cells. Nutr Cancer 2022;:1-8. [PMID: 35040364 DOI: 10.1080/01635581.2022.2028866] [Reference Citation Analysis]
152 Sim HW, McDonald KL, Lwin Z, Barnes EH, Rosenthal M, Foote MC, Koh ES, Back M, Wheeler H, Sulman EP, Buckland ME, Fisher L, Leonard R, Hall M, Ashley DM, Yip S, Simes J, Khasraw M. A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol 2021:noab111. [PMID: 33984151 DOI: 10.1093/neuonc/noab111] [Reference Citation Analysis]
153 Anghileri E, Patanè M, Di Ianni N, Sambruni I, Maffezzini M, Milani M, Maddaloni L, Pollo B, Eoli M, Pellegatta S. Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches. Cancers (Basel) 2021;13:6156. [PMID: 34944776 DOI: 10.3390/cancers13246156] [Reference Citation Analysis]
154 Zhang Y, Xi K, Fu X, Sun H, Wang H, Yu D, Li Z, Ma Y, Liu X, Huang B, Wang J, Li G, Cui J, Li X, Ni S. Versatile metal-phenolic network nanoparticles for multitargeted combination therapy and magnetic resonance tracing in glioblastoma. Biomaterials 2021;278:121163. [PMID: 34601197 DOI: 10.1016/j.biomaterials.2021.121163] [Reference Citation Analysis]
155 Liu F, Wu H, Peng B, Zhang S, Ma J, Deng G, Zou P, Liu J, Chen AT, Li D, Bellone S, Santin AD, Moliterno J, Zhou J. Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia-Chemotherapy Combination for Brain Cancer Treatment. Nano Lett 2021;21:8111-8. [PMID: 34597054 DOI: 10.1021/acs.nanolett.1c02459] [Reference Citation Analysis]
156 Ding Y, Zhang C, He L, Song X, Zheng C, Pan Y, Yu S. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Bioengineered 2021;12:10791-8. [PMID: 34753395 DOI: 10.1080/21655979.2021.2003927] [Reference Citation Analysis]
157 Song J, Zhang H, Wang D, Wang J, Zhou J, Zhang Z, Wang J, Hu Y, Xu Q, Xie C, Lu W, Liu M. Hydrogel loading functionalized PAMAM/shRNA complex for postsurgical glioblastoma treatment. J Control Release 2021;338:583-92. [PMID: 34481020 DOI: 10.1016/j.jconrel.2021.08.052] [Reference Citation Analysis]
158 Zalles M, Smith N, Saunders D, Guzman M, Lerner M, Fung KM, Babu A, Battiste J, Chung J, Hwang K, Jin J, Towner RA. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies. Neurooncol Adv 2021;3:vdab132. [PMID: 34704036 DOI: 10.1093/noajnl/vdab132] [Reference Citation Analysis]
159 McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, diagnosis, and management. BMJ 2021;374:n1560. [PMID: 34261630 DOI: 10.1136/bmj.n1560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Qin H, Gui Y, Ma R, Zhang H, Guo Y, Ye Y, Li J, Zhao L, Wang Y. miR-1258 Attenuates Tumorigenesis Through Targeting E2F1 to Inhibit PCNA and MMP2 Transcription in Glioblastoma. Front Oncol 2021;11:671144. [PMID: 34079762 DOI: 10.3389/fonc.2021.671144] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Akcora-Yildiz D, Yukselten Y, Sunguroglu M, Ugur HC, Sunguroglu A. IL-33 induces ADAMTS5 expression and cell migration in glioblastoma multiforme. Med Oncol 2022;39:22. [PMID: 34982269 DOI: 10.1007/s12032-021-01590-y] [Reference Citation Analysis]
162 Soni V, Adhikari M, Simonyan H, Lin L, Sherman JH, Young CN, Keidar M. In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma. Cancers (Basel) 2021;13:4485. [PMID: 34503293 DOI: 10.3390/cancers13174485] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Zhang K, Zhao H, Zhang K, Hua C, Qin X, Xu S. Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma. Ann Transl Med 2020;8:1594. [PMID: 33437793 DOI: 10.21037/atm-20-7229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Ji YR, Cheng CC, Lee AL, Shieh JC, Wu HJ, Huang AP, Hsu YH, Young TH. Poly(allylguanidine)-Coated Surfaces Regulate TGF-β in Glioblastoma Cells to Induce Apoptosis via NF-κB Pathway Activation. ACS Appl Mater Interfaces 2021;13:59400-10. [PMID: 34846137 DOI: 10.1021/acsami.1c21027] [Reference Citation Analysis]
165 Torrisi F, Alberghina C, Lo Furno D, Zappalà A, Valable S, Li Volti G, Tibullo D, Vicario N, Parenti R. Connexin 43 and Sonic Hedgehog Pathway Interplay in Glioblastoma Cell Proliferation and Migration. Biology (Basel) 2021;10:767. [PMID: 34439999 DOI: 10.3390/biology10080767] [Reference Citation Analysis]